CY1113540T1 - Εμβολια γριππης σκυλων - Google Patents

Εμβολια γριππης σκυλων

Info

Publication number
CY1113540T1
CY1113540T1 CY20131100029T CY131100029T CY1113540T1 CY 1113540 T1 CY1113540 T1 CY 1113540T1 CY 20131100029 T CY20131100029 T CY 20131100029T CY 131100029 T CY131100029 T CY 131100029T CY 1113540 T1 CY1113540 T1 CY 1113540T1
Authority
CY
Cyprus
Prior art keywords
vaccine
influenza
vaccines
vaccine vaccines
dog vaccine
Prior art date
Application number
CY20131100029T
Other languages
English (en)
Inventor
Jules Maarten Minke
Kemal Karaca
Jiansheng Yao
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/211,983 external-priority patent/US7384642B2/en
Application filed by Merial Limited filed Critical Merial Limited
Publication of CY1113540T1 publication Critical patent/CY1113540T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση περιλαμβάνει εμβόλια γρίππης, ιδίως εμβόλια γρίππης σκύλων. Το εμβόλιο μπορεί να είναι ανασυνδυασμένο εμβόλιο ή απενεργοποιημένο εμβόλιο ιού ευλογιάς. Η εφεύρεση περιλαμβάνει επίσης φορείς ανασυνδυασμένου ιού ευλογιάς που κωδικοποιούν και εκφράζουν αντιγόνα, επιτόπους ή ανοσογόνα ιού γρίππης που μπορούν να χρησιμοποιηθούν για να προστατεύουν ζώα, ιδίως σκύλους, από γρίππη.
CY20131100029T 2005-08-25 2013-01-11 Εμβολια γριππης σκυλων CY1113540T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/211,983 US7384642B2 (en) 2005-08-25 2005-08-25 Canine influenza vaccines
US11/264,622 US7425336B2 (en) 2005-08-25 2005-11-01 Canine influenza vaccines
EP06789953A EP1942933B1 (en) 2005-08-25 2006-08-23 Canine influenza vaccines

Publications (1)

Publication Number Publication Date
CY1113540T1 true CY1113540T1 (el) 2016-06-22

Family

ID=37772325

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100029T CY1113540T1 (el) 2005-08-25 2013-01-11 Εμβολια γριππης σκυλων

Country Status (11)

Country Link
US (1) US7425336B2 (el)
EP (1) EP1942933B1 (el)
JP (1) JP2009506050A (el)
CA (1) CA2620074C (el)
CY (1) CY1113540T1 (el)
DK (1) DK1942933T3 (el)
ES (1) ES2397707T3 (el)
PL (1) PL1942933T3 (el)
PT (1) PT1942933E (el)
SI (1) SI1942933T1 (el)
WO (1) WO2007024947A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20080241184A1 (en) * 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
NZ566490A (en) * 2005-10-07 2011-06-30 Pfizer Prod Inc Live attenuated or killed H3N8 influenza vaccines and methods to treat canine influenza
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US8697087B2 (en) * 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
ES2420829T3 (es) * 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
WO2010114169A1 (en) * 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2011094693A1 (en) * 2010-02-01 2011-08-04 Mount Sinai School Of Medicine Interferon-inducing compounds and uses thereof
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
US10478489B2 (en) 2015-08-20 2019-11-19 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017210528A1 (en) 2016-06-03 2017-12-07 University Of Rochester Equine influenza virus live-attenuated vaccines
AU2017286727B2 (en) 2016-06-17 2024-02-08 Boehringer Ingelheim Animal Health USA Inc. Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
CN111989116A (zh) 2018-02-27 2020-11-24 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5756430A (en) * 1980-09-19 1982-04-05 Biseibutsu Kagaku Kenkyusho:Kk Live virus vaccine for canine parainfluenza
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
SG10201910006WA (en) * 2005-04-21 2019-11-28 Univ Florida Materials and methods for respiratory disease control in canines

Also Published As

Publication number Publication date
WO2007024947A2 (en) 2007-03-01
PL1942933T3 (pl) 2013-03-29
DK1942933T3 (da) 2013-01-14
US20070048821A1 (en) 2007-03-01
CA2620074A1 (en) 2007-03-01
SI1942933T1 (sl) 2013-02-28
EP1942933A2 (en) 2008-07-16
JP2009506050A (ja) 2009-02-12
ES2397707T3 (es) 2013-03-08
CA2620074C (en) 2014-07-15
WO2007024947A3 (en) 2007-05-31
PT1942933E (pt) 2013-01-24
US7425336B2 (en) 2008-09-16
EP1942933B1 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
CY1113540T1 (el) Εμβολια γριππης σκυλων
CY1124015T1 (el) Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδiκευοντας ενα ετερολογο αντιγονο που απομονωνεται απο ιο ηπατιτιδας β και χρησεις εξ αυτων
CY1124218T1 (el) Ανασυνδυασμενοι αδενοϊικοi φορεις εμβολιων fmdv και χρησεις αυτων
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
CY1119650T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
BRPI0923599A2 (pt) vírus da febre suína clássica recombinante, vacina para febre suína clássica viva, métodos para proteger um animal contra a febre suína clássica, para diferenciar animais infectados com o vírus da febre suína clássica de animais não infectados ou de animais vacinados com a vacina para febre suína clássica, e para isolar um vírus da febre suína clássica recombinante infeccioso, molécula de cdna, uso do vírus da febre suína clássica recombinante infeccioso, e, elisa com base em peptídeo
WO2006115843A3 (en) Nipah virus vaccines
ATE528016T1 (de) Virusähnliche partikel als paramyxovirus- impfstoffe
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
CY1113970T1 (el) Κατασκευες και φορεις μεταφορας αντιγονων
MY159543A (en) Recombinant avian influenza vaccine and uses thereof
EP2944322A3 (en) Bluetongue virus recombinant vaccines and uses thereof
EP3156070A3 (en) Newcastle disease virus vectored herpesvirus vaccines
CY1118573T1 (el) Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων
DOP2012000187A (es) Antigeno ndv recombinante y usos del mismo
BR112022014830A2 (pt) Formulações de vacina para coronavírus
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
AR047581A1 (es) Vacunas de calicivirus felino
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina
DK3471766T3 (da) Rekombinante, ikke-patogene mareks sygdomsviruskonstrukter, der koder for infektiøs laryngotracheitisvirus- og infektiøs bursitis virus-antigener patentkrav